Revised Hippocratic Oath resonates with graduates

Revisiting a hallowed ritual for doctors, a committee within the Weill Cornell Medical College convened this spring to craft an updated Hippocratic Oath, one that responds to the state of modern medicine. Written in ancient Greece, the oath expresses principles still fundamental to the practice of medicine today. (June 22, 2005)

Weill Cornell/ludwig institute for cancer research collaboration identifies two antigens as targets for multiple myeloma vaccine

Vaccines that train the immune system to seek out and destroy malignant cells are at the cutting edge of cancer treatment. Now, joint research – conducted by researchers at Weill Medical Cornell and at the Ludwig Institute for Cancer Research Memorial Sloan-Kettering Cancer Center Branch in New York – has pinpointed two proteins that seem ideal targets for a vaccine against multiple myeloma.

Extensive brain activity while listening to speech suggests awareness in minimally conscious patients

For the first time, advanced neurological imaging suggests the brains of minimally conscious patients recognize and respond to speech in ways similar to healthy individuals, according to a team of researchers. (Feb. 7, 2005)

Silencing human gene through new science of epigenetics

For the first time, scientists have shown how the activity of a gene associated with normal human development, as well as the occurrence of cancer and several other diseases, is repressed epigenetically – by modifying not the DNA code of a gene, but instead the spool-like histone proteins around which DNA tightly wraps itself in the nucleus of cells in the body.

In mouse model, Weill Cornell researchers use gene therapy to correct deadly inherited immune disorder

Previous attempts in mice to correct a rare inherited immune disorder, called Hyper IgM X-linked immunodeficiency, have failed because standard gene therapy raised risks for cancer. Now Weill Cornell Medical College researchers believe they've found a way around that problem.

Phase i clinical trial of monoclonal antibody treatment for advanced prostate cancer demonstrates evidence of anti-tumor activity

Researchers at NewYork-Presbyterian/Weill Cornell Report Findings of Phase I Clinical Trial of Monoclonal Antibody Treatment for Advanced Prostate Cancer.

Weill Cornell launches new stem cell center with $15 million grant

The Board of Overseers of Weill Cornell Medical College in New York City voted today to establish the new Ansary Center for Stem Cell Therapeutics. The unique Center will bring together a premier team of scientists to focus on stem cells – the primitive, unspecialized cells thought to have an unrivaled capacity to form all types of cells in the body.

New York-Presbyterian/Weill Cornell researchers discover non-protease inhibitor drug combo better than others for fighting HIV

A certain combination of AIDS drugs is superior to others when it comes to the initial treatment of HIV patients, NewYork-Presbyterian Hospital/Weill Cornell Medical Center researchers report in the New England Journal of Medicine.

New York Weill Cornell discovers anti-cancer drug tamoxifen boosts fertility in breast cancer patients

The Center for Reproductive Medicine and Infertility at NewYork Weill Cornell Medical Center has discovered that the wonder drug tamoxifen can help breast cancer patients have babies - even after they experience fertility loss associated with chemotherapy.